Original Publication Date: 1 October, 2014
Publication / Source: Future Oncology
Authors: Robert Goldstein, Dominic Yu, Roopinder Gillmore et al
Aims: Sorafenib is the only standard therapy for advanced hepatocellular carcinoma, but has a low response rate. Leucovorin and oxaliplatin (FOLFOX) has a superior response rate versus doxorubicin among Asian sorafenib-naive patients. We aimed to retrospectively review the outcome of 20 consecutive patients treated with FOLFOX at a single European center.